PolarX vs Arctic Front for Cryoballoon Ablation of Paroxysmal AF: The Randomized COMPARE CRYO Study. ...

BACKGROUND Pulmonary vein isolation is an effective treatment for atrial fibrillation (AF). Cryoballoon ablation using the Arctic Front cryoballoon (Medtronic) was found to be superior to antiarrhythmic drug treatment. Recently, a novel cryoballoon system was introduced (PolarX, Boston Scientific)....

Full description

Bibliographic Details
Main Authors: Reichlin, Tobias, Kueffer, Thomas, Knecht, Sven, Madaffari, Antonio, Badertscher, Patrick, Maurhofer, Jens, Krisai, Philipp, Jufer, Corinne, Asatryan, Babken, Heg, Dik, Servatius, Helge, Tanner, Hildegard, Kühne, Michael, Roten, Laurent, Sticherling, Christian
Format: Text
Language:unknown
Published: Elsevier 2024
Subjects:
610 Medicine & health
Arctic
Online Access:https://dx.doi.org/10.48350/196869
https://boris.unibe.ch/196869/
Description
Summary:BACKGROUND Pulmonary vein isolation is an effective treatment for atrial fibrillation (AF). Cryoballoon ablation using the Arctic Front cryoballoon (Medtronic) was found to be superior to antiarrhythmic drug treatment. Recently, a novel cryoballoon system was introduced (PolarX, Boston Scientific). OBJECTIVES The purpose of this study was to compare the efficacy and safety of the 2 cryoballoons in a randomized controlled trial. METHODS Patients with symptomatic paroxysmal AF were enrolled in 2 centers and randomized 1:1 to pulmonary vein isolation using the PolarX or the Arctic Front cryoballoon. All patients received an implantable cardiac monitor. The primary endpoint was first recurrence of atrial tachyarrhythmia (AF, atrial flutter, or atrial tachycardia [AT]) between days 91 and 365. Procedural safety was assessed by a composite of tamponade, phrenic nerve palsy lasting >24 hours, vascular complications, stroke/transient ischemic attack, atrioesophageal fistula or death up to 30 days. RESULTS A total ...

Similar Items